Opendata, web and dolomites

IBL-302

Inflection Bioscience unique dual mechanism, small molecule, orally available therapeutic targeting major unmet medical needs in breast cancer

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "IBL-302" data sheet

The following table provides information about the project.

Coordinator
INFLECTION BIOSCIENCES LIMITED 

Organization address
address: SUITE 15, ANGLESEA HOUSE, CARYSFORT AVENUE
city: BLACKROCK DUBLIN
postcode: A94Y R59
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Ireland [IE]
 Project website http://www.inflectionbio.com/pipeline/dual-mechanism-kinase-inhibitors-pim-kinase-pi3k.236.html
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-06-01   to  2019-09-30

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    INFLECTION BIOSCIENCES LIMITED IE (BLACKROCK DUBLIN) coordinator 50˙000.00

Map

 Project objective

Breast cancer is already a leading cause of death among women and most common form of cancer among European women with almost 500,000 cases in 2012 and over 1.7 million new cases globally. However, despite good progress in treatment options over the past decade, including some progress with immunotherapies, the war is far from won, with over 20% not responding to current standard care, and with the incidence of breast cancer set to rise by a massive 50% by 2030. There is now an urgent need for new effective, safe and life extending therapeutics for those women suffering and dying with breast cancer. IBL-302 is a first-in-class small molecule targeted breast cancer therapeutic that targets both the PI3K and PIM pathways. It is an orally bioavailable pan-PIM kinase, pan-PI3K and mTOR inhibition in a single agent. As the PI3K pathway is one of the most commonly mutated pathways, this multi-path action effect closes down the main route of mutation and a primary backup PIM pathway. This confers the promise of much greater rates of efficacy and potential utility to combat the breast cancer epidemic. Inhibition of the PI3K pathway alone is cytostatic, it pauses cell growth but does not kill cancer cells. This has the effect of the PIM pathways then being activated as a backup mutation pathway, allowing the cancer to progress once more. Adding PIM inhibition on top of the PI3K inhibition actually induces apoptosis, the death of cancer cells instead of simply stalling their growth. A development partnership will be sought with a large pharmaceutical company to complete final stages of clinical development required for market approval. The partner will also be responsible for the manufacture and distribution IBL-302 on an exclusive licence.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IBL-302" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IBL-302" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

QTB4AMR (2019)

Utilizing an innovative chemical platform to defeat antimicrobial resistance

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More